ABSTRACT
Background
An effective therapy to reduce the number and severity of HLA-B27-related acute anterior uveitis (AAU) recurrences represents a clinical need. Curcumin is a promising therapeutic option in various inflammatory eye diseases. To enhance its absorption and eye tissue selectivity, a phospholipidic-curcumin complex (PHBC) has been formulated (Iphytoone®, Eye Pharma S.p.A.).
Aims
This study investigates if PHBC is effective and safe to decrease the number and intensity of HLA-B27-related AAU relapses.
Methods
HLA-B27-related AAU patients were randomly divided to receive PHBC or placebo for 12 months (NCT03584724).
Results
Compared with the previous year, the number of relapses decreased in both groups. The proportion of responders was significantly higher in the PBHC group. The severity of attacks was comparable. The study drug was well tolerated.
Conclusions
A beneficial effect of PHBC treatment is suggested because the proportion of responders was significantly higher in this group of patients.
Acknowledgments
Editorial assistance was provided by Simonetta Papa, PhD, and Aashni Shah (Polistudium SRL, Milan, Italy). This assistance was supported by Eye Pharma S.p.A.
Authors’ contributions
Study design: All; data collection and interpretation: All; manuscript writing: Pia Allegri, Ilknur Tugal-Tutkun; manuscript editing and approval to submit: All.
Consent to participate
All the participants signed an informed consent form.
Consent for publication
Not required as this manuscript doesn’t include details, images or videos related to the participants.
Disclosure statement
No potential conflict of interest was reported by the author(s).
Data availability statement
Data may be made available upon reasonable request.
Ethics approval
The study was approved by the institutional review board of each center and was conducted in compliance with Good Clinical Practices, including the archiving of essential documents.